Company Intelligence

10x Science

10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development. AI-powered drug discovery is flooding the pipeline with new candidates faster…

In this profile

Quick Facts

  • Founded 2026
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Enterprise Software
  • Company Type Early
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development.

AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early.

We have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.

Why It Matters

The AI-native platform for next-generation protein characterization.

Products

Recent Developments

  1. 2026 Company founded

    10x Science was founded in 2026 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development.

AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early.

We have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi’s Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe